𝔖 Bobbio Scriptorium

✦ LIBER ✦

Major response and clinical benefit following third-line treatment for Bellini duct carcinoma

✍ Scribed by Negar Fakhrai; Andrea Haitel; Csilla Balassy; Christoph C. Zielinski; Manuela Schmidinger

Book ID: 106171712
Publisher: Springer Vienna
Year: 2005
Tongue: English
Weight: 108 KB
Volume: 117
Category: Article
ISSN: 0043-5325
DOI: 10.1007/s00508-004-0289-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5031 Overall response rate (ORR) and cli

5031 Overall response rate (ORR) and clinical benefit (CB) as clinical indicators for the efficacy of sequential Aromatase Inhibitors (AIs) in 3rd line hormonal treatment (HT) for advanced breast cancer (ABC): pooled analysis of phase II studies

✍ V. Vaccaro; E. Bria; F. Cuppone; M. Milella; C. Nisticò; I. Sperduti; D. Giannar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB